TradeFlare's AI research teams analysed ALXO on 6 market nights between July 31, 2026 and August 14, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 14, 2026 | HOLD | $1.94 | — / — | +4.1% | -1.8% | The current market regime and stock-specific factors do not support a new entry. |
| August 12, 2026 | HOLD | $1.93 | — / — | +2.5% | -5.5% | Promising clinical data from ongoing trials. |
| August 6, 2026 | BUY | $1.92 | — / — | -8.1% | -3.8% | Positive clinical trial readouts for pipeline candidates. |
| August 4, 2026 | BUY | $1.93 | — / — | -2.0% | +0.5% | Advancements in drug programs driving neutral news sentiment. |
| August 3, 2026 | HOLD | $1.94 | — / — | +6.7% | +0.0% | Upcoming clinical readouts for ALXO's lead candidate. |
| July 31, 2026 | BUY | $1.95 | — / — | +8.2% | +3.1% | Positive clinical trial data for evorpacept. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.